Validation of an Individualized Measure of Quality of Life, Patient Generated Index, for Use with People with Parkinson's Disease.

IF 1.7 Q4 NEUROSCIENCES

Neurology Research International Pub Date : 2020-03-30 eCollection Date: 2020-01-01 DOI:10.1155/2020/6916135

Ayse Kuspinar, Kedar K V Mate, Anne-Louise Lafontaine, Nancy Mayo

{"title":"Validation of an Individualized Measure of Quality of Life, Patient Generated Index, for Use with People with Parkinson's Disease.","authors":"Ayse Kuspinar, Kedar K V Mate, Anne-Louise Lafontaine, Nancy Mayo","doi":"10.1155/2020/6916135","DOIUrl":null,"url":null,"abstract":"Methods: Patients with PD completed the PGI and various standard patient-reported outcome (PRO) measures. The PGI and standard PRO measures were compared at the total score, domain, and item levels. Pearson's correlations and independent t-tests were used, as well as positive and negative predictive values.Results: The sample (n = 76) had a mean age of 69 (standard deviation 9) and were predominantly men (59%). The PGI was moderately correlated (r = -0.35) with the standardized disease-specific QOL measure Parkinson's Disease Questionnaire (PDQ-8). Within one severity rating, agreement between the PGI and different standard outcome measures ranged from 85 to 100% for walking, 69 to 100% for fatigue, 38 to 75% for depression, and 20 to 80% for memory/concentration.Conclusion: This study demonstrates that nominated areas of QOL on the PGI provide comparable results to standard PRO measures, and provides evidence in support of the validity of this individualized measure in PD.","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2020 ","pages":"6916135"},"PeriodicalIF":1.7000,"publicationDate":"2020-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/6916135","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology Research International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/6916135","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 2

Abstract

Methods: Patients with PD completed the PGI and various standard patient-reported outcome (PRO) measures. The PGI and standard PRO measures were compared at the total score, domain, and item levels. Pearson's correlations and independent t-tests were used, as well as positive and negative predictive values.

Results: The sample (n = 76) had a mean age of 69 (standard deviation 9) and were predominantly men (59%). The PGI was moderately correlated (r = -0.35) with the standardized disease-specific QOL measure Parkinson's Disease Questionnaire (PDQ-8). Within one severity rating, agreement between the PGI and different standard outcome measures ranged from 85 to 100% for walking, 69 to 100% for fatigue, 38 to 75% for depression, and 20 to 80% for memory/concentration.

Conclusion: This study demonstrates that nominated areas of QOL on the PGI provide comparable results to standard PRO measures, and provides evidence in support of the validity of this individualized measure in PD.

Abstract Image

查看原文本刊更多论文

用于帕金森病患者的个性化生活质量测量的验证，患者生成指数。

方法:PD患者完成PGI和各种标准患者报告结果(PRO)测量。在总分、领域和项目水平上比较PGI和标准PRO测量。使用Pearson相关和独立t检验，以及正预测值和负预测值。结果:样本(n = 76)平均年龄为69岁(标准差为9)，以男性为主(59%)。PGI与标准化疾病特异性生活质量测量帕金森病问卷(PDQ-8)中度相关(r = -0.35)。在一个严重程度等级中，PGI与不同标准结果测量之间的一致性范围从步行的85%到100%，疲劳的69到100%，抑郁的38到75%，记忆/注意力的20到80%。结论:本研究表明，PGI上指定的生活质量区域与标准PRO测量结果相当，并提供证据支持该个性化测量在PD中的有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurology Research International NEUROSCIENCES-

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

17 weeks

期刊介绍： Neurology Research International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies focusing on diseases of the nervous system, as well as normal neurological functioning. The journal will consider basic, translational, and clinical research, including animal models and clinical trials.